Biogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies in the United ...

Biogen’s diranersen showed ‘robust reductions’ in key biomarkers during a Phase 2 trial, the biotech said.

Biogen (NasdaqGS:BIIB) has completed its acquisition of Apellis Pharmaceuticals, adding marketed drugs in complement-driven diseases and nephrology to its portfolio. The company has moved its first-in ...

Biogen before the bell said its treatment, diranersen, demonstrated slowing of clinical decline in early Alzheimer's disease across all studied doses in a recent trial. The safety ...

Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of quarterly earnings, and investors greeted the estimates-beating numbers by piling ...

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the ...

Healthcare company Biogen (NASDAQ: BIIB) wasn't looking very healthy on the stock market on Monday. Investors traded out of its shares after learning that the company plans to book a hefty charge in ...

In August, the U.S. Food and Drug Administration (FDA) stated that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare but ...

Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...